SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Amazon Secures 200 MW Wind Power Deals in Sweden 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Toyota Global Sales Fall as China Demand Slumps 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Add as a preferred source on Google
SINGAPORE, April 17, 2018 -- ASLAN Pharmaceuticals (ASLAN) (6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the presentation of new data from a study of the use of varlitinib in hepatocellular carcinoma (HCC) at the American Association for Cancer Research (AACR) 2018 Annual Meeting in Chicago, Illinois.
| Details of the poster are as below: | ||
| Session: | Experimental and Molecular Therapeutics | |
| Poster #: | 3992 / 26 | |
| Section: | 41 | |
| Title: | Varlitinib demonstrates tumor regression and vessel normalization in ErbB-dependent and mutated beta-catenin hepatocellular carcinoma patient-derived xenograft model | |
The pre-clinical study was conducted in collaboration with the National Cancer Centre Singapore (NCCS) and was led by Professor The Huynh Hung, Principal Investigator at NCCS’ Laboratory of Molecular Endocrinology. The study was designed to demonstrate the efficacy of varlitinib in HCC patient-derived xenograft (PDX) models and to study the molecular mechanisms of varlitinib-mediated tumor suppression and its anti-angiogenic potential. In addition, the study sought to identify gene signatures associated with efficacy of varlitinib by transcriptome and gene expression analyses.
About varlitinib (ASLAN001)
Varlitinib (ASLAN001) is a highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4. These receptors can be mutated or overexpressed in many tumors, which can cause excessive proliferative activity and uncontrolled growth. Therefore, by inhibiting the activation of the HER receptors, varlitinib could inhibit proliferation and control tumor growth. Varlitinib is currently being studied in gastric, biliary tract, breast and colorectal cancers. Varlitinib has been granted orphan drug designation in the United States for gastric cancer and cholangiocarcinoma, a sub-type of biliary tract cancer, and was awarded orphan drug designation for the treatment of biliary tract cancer by the Ministry of Food and Drug Safety in South Korea.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (ASLAN, 6497.TT) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialization, ASLAN is headquartered in Singapore and has offices in Taiwan and China. ASLAN’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. ASLAN’s partners include Array BioPharma, Bristol-Myers Squibb, Almirall and CSL. For additional information please visit www.aslanpharma.com.
Media and IR contacts Chris Fang ASLAN Pharmaceuticals Tel: +886 2 2758 3333 Email: [email protected] Emma Thompson / Stephanie Tan Spurwing Communications Tel: +65 6340 7287 Email: [email protected] Robert H Uhl Westwicke Partners Tel: +1 858 356 5932 Email: [email protected]
